Neprilysin inhibitors potentiate effects of bradykinin on B2 receptor

Hypertension

Volumn 39, Issue 2 II, 2002, Pages 619-623

  Deddish, Peter A ^a   Marcic, Branislav M ^a   Tan, Fulong ^a   Jackman, Herbert L ^a   Chen, Zhenlong ^a   Erdös, Ervin G ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Angiotensin converting enzyme; Arachidonic acids; Calcium; Fibroblasts; G proteins; Receptors, bradykinin

Indexed keywords

ARACHIDONIC ACID; BRADYKININ; BRADYKININ B2 RECEPTOR; BRADYKININ DERIVATIVE; BRADYKININ[8 PHENYLALANINE 9 ARGININE] AMIDE; CALCIUM ION; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENKEPHALINASE INHIBITOR; ICATIBANT; MEMBRANE METALLOENDOPEPTIDASE; OMAPATRILAT; PHOSPHORAMIDON; UNCLASSIFIED DRUG;

ANIMAL CELL; CALCIUM CELL LEVEL; CHO CELL; CONFERENCE PAPER; CONTROLLED STUDY; DESENSITIZATION; DRUG EFFECT; DRUG POTENTIATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LUNG FIBROBLAST; NONHUMAN; PRIORITY JOURNAL; SENSITIZATION;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; BRADYKININ; CELLS, CULTURED; CHO CELLS; CRICETINAE; DRUG SYNERGISM; HUMANS; HYDROLYSIS; NEPRILYSIN; PYRIDINES; RECEPTOR, BRADYKININ B2; RECEPTORS, BRADYKININ; THIAZEPINES; TRANSFECTION;

EID: 0036176432     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/hy0202.103298     Document Type: Conference Paper

References (30)

1. Metabolism of bradykinin by peptidases in health and disease
2. Human kidney "enkephalinase", a neutral metalloendopeptidase that cleaves active peptides
3. Neutral endopeptidase 24.11-enkephalinase and related regulators of peptide hormones
4. The purification and specificity of a neutral endopeptidase from rabbit kidney brush border
5. Angiotensin I-converting enzyme in the nephron
6. Ultrastructural localization of angiotensin I-converting enzyme (EC 3.4.15.1) and neutral metalloendopeptidase (EC 3.4.24.11) in the proximal tubule of the human kidney
7. Neutral metalloendopeptidase in human male genital tract. Comparison to angiotensin I-converting enzyme
8. Identification and characterization of neutral endopeptidase in endothelial cells from venous or arterial origins
9. Neutral metalloendopeptidase in human lung tissue and cultured cells
10. The two homologous domains of human angiotensin I-converting enzyme are both catalytically active
11. Transformation of the signal peptide/membrane anchor domain of a type II transmembrane protein into a cleavable signal peptide
12. Human converting enzyme
13. Neutral endopeptidase in the heart: Neutral endopeptidase inhibition prevents isoproterenol-induced myocardial hypoperfusion in rats by reducing bradykinin degradation
14. Effect of phosphoramidon, a kininase inhibitor, in renal function and kinin excretion
15. 2 receptor selective agonist which is not broken down by either kininase I or kininase II
16. Replacement of the transmembrane anchor in angiotensin I-converting enzyme (ACE) with a glycosylphosphatidylinositol tail affects activation of the B2 bradykinin receptor by ACE inhibitors
17. Potentiation of the actions of bradykinin by angiotensin I converting enzyme (ACE) inhibitors: The role of expressed human bradykinin B2 receptors and ACE in CHO cells
18. Purification and specificity of a membrane-bound metalloendopeptidase from bovine pituitaries
19. Expression cloning of a human BI bradykinin receptor
20. Enzyme Kinetics
21. 2 receptor
22. Protein kinase C and phosphatase inhibitors block the ability of angiotensin I-converting enzyme inhibitors to resensitize the receptor to bradykinin without altering the primary effects of bradykinin
23. Kinins, receptors, kininases and inhibitors - Where did they lead us?
24. Role of angiotensin and its inhibition in hypertension, ischemic heart disease, and heart failure
25. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the Survival and Ventricular Enlargement Trial
26. Potentiation of the effects of bradykinin on its receptor in the isolated guinea pig ileum
27. Angiotensin I-converting enzyme inhibitors potentiate bradykinin's inotropic effects independently of blocking its inactivation
28. Bradykinin potentiation by angiotensin-(1-7) and ACE inhibitors correlates with ACE C- and N-domain blockade
29. Bioregulation of kinins: Kallikreins, kininogens, and kininases
30. Vasopeptidase inhibitors: An emerging class of cardiovascular drugs